Navigation Links
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
Date:5/4/2009

.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), rheumatoid arthritis, multiple sclerosis, psoriasis, and dermatology. The company is also aiming to expand its development pipeline though licensing-in in the areas mentioned plus some others including gastrointestinal and neurology.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates (Austria, Belgium, France, Germany, Italy, Mexico, Poland, Portugal, Spain, Switzerland, and the UK-Ireland). For further information please visit the website at: www.almirall.com.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. Linaclotide, the company's first in class compound, is being evaluated in a comprehensive Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia, Inc. (formerly Microbia Precision Engineering), a majority-owned subsidiary of Ironwood, is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Ironwood has raised $281 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com


'/>"/>
SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
5. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... VIEW, Calif. , June 3, 2015 /PRNewswire/ ... healthcare sector around the globe and keeping track ... in this competitive market. In particular, ensuring user-friendliness, ... detection sensitivity are the most important factors influencing ... their consumer base. New analysis from ...
(Date:6/3/2015)... MALVERN, Pa. , June 3, 2015  Essential ... today that it has been invited to speak at ... New York city on June 4th.  ... Large Bore closure system, including a review of first ... systems.     MANTA closes femoral arterial punctures ...
(Date:6/3/2015)... aTyr Pharma, Inc. (NASDAQ: LIFE ), a biotherapeutics company ... address rare diseases, today announced the Company,s participation at the ... be held at the Four Seasons Hotel in ... John Mendlein , aTyr,s CEO and Executive Chairman, is scheduled ... CT on Wednesday, June 10, 2015. The presentation will be ...
Breaking Medicine Technology:Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2
(Date:6/3/2015)... Loma Linda University Health and Adventist Health ... Memorial Hospital (SGMH). The SGMH board voted unanimously to ... “Loma Linda University Health has been serving the Pass ... officer, Loma Linda University Medical Center. “We are thrilled ... this community.” , Under the proposed affiliation, Loma ...
(Date:6/3/2015)... “ Harmony ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... aspect of their life. , A common mistake people make ... in their life. However, hypnotherapy is intended for anyone who ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
Breaking Medicine News(10 mins):Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
... Alan Mozes HealthDay Reporter , TUESDAY, May 15 ... silver bullet when it comes to symptom relief for acute ... of six prior studies found that the sprays confer only ... for three weeks at relatively high doses. The disappointing ...
... May 15 (HealthDay News) -- Should Americans be able to buy ... they,re infected with the virus that causes AIDS? , , A ... question Tuesday, and the answer the panel arrives at could pave ... advisory panel recommendations are not binding, but they are often followed ...
... KNOX, Ky., May 15, 2012 The U.S. Army Medical ... to Mastership in the American College of Physicians (MACP). Only ... eminence through their contributions to the field of internal medicine ... or volunteerism, were awarded a Mastership in 2012. One of ...
... Child,s Age and Severity of Gait Abnormality ,Most ... 2. And while some toe walkingwhere a child primarily walks ... the heel to the groundis common, persistent toe walking beyond ... article, "Idiopathic Toe Walking," outlines the appropriate steps for effectively ...
... Center at HakensackUMC, one of the nation,s top 50 cancer ... year,s program, titled New Horizons in Neuro-Oncology- Innovations in the ... the most important advancements and innovations for the treatment of ... on Friday, May 18 from 8:00am to 1:00pm. ...
... a way to save money while having little effect on ... study. Researchers say that 57.6 percent of patients ... schizophrenia or bipolar disorder, the conditions for which the drugs ... is not FDA-approved is called off-label use. "Given ...
Cached Medicine News:Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:FDA Panel to Consider At-Home HIV Test 2Health News:FDA Panel to Consider At-Home HIV Test 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 2Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 4Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium 2Health News:Reducing off-label use of antipsychotic medications may save money 2Health News:Reducing off-label use of antipsychotic medications may save money 3
These backbiters enable simple access to the anterior horn of the meniscus....
ACUFEX Loop Handle. Blunt nose basket punch enables flush contouring of meniscus....
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: